Viridian Therapeutics, Inc. - Common Stock — 재무제표 (NASDAQ:VRDN) | MetaTrader

전체 차트 열기 Full chart

Financials

개요 성명 통계

총자산 131.25 M203.71 M435.09 M490.42 M742.4 M899.42 M 총 부채 11.22 M15.99 M40.03 M48.4 M70.76 M177.25 M 자본금 총액 120.04 M187.72 M395.06 M442.02 M671.64 M722.17 M 총 부채 및 주주자본 131.25 M203.71 M435.09 M490.42 M742.4 M899.42 M 총부채 0———20.58 M84.18 M 순부채 -127.6 M———-697.02 M-790.52 M

뉴스

Viridian Therapeutics, Inc. (VRDN) Discusses Positive Top Line Results From REVEAL-2 Phase III Trial in Chronic Thyroid Eye Disease - Slideshow (NASDAQ:VRDN) 2026-05-09

Viridian Therapeutics, Inc. (VRDN) Discusses Positive Top Line Results From REVEAL-2 Phase III Trial in Chronic Thyroid Eye Disease Transcript

Can This Small Rival Take On Amgen's Eye Disease Blockbuster?

Viridian Therapeutics: Why Elegrobart Phase 3 Results Fail To Challenge Amgen (NASDAQ:VRDN)

Amgen Unveils Upbeat Results For Tepezza After Rival Eye Disease Drug Disappoints

Viridian Therapeutics, Inc. (VRDN) Discusses Positive Topline Results from Elegrobart REVEAL-1 Phase III Trial in Active Thyroid Eye Disease - Slideshow (NASDAQ:VRDN) 2026-04-02

Viridian Therapeutics, Inc. (VRDN) Discusses Positive Topline Results from Elegrobart REVEAL-1 Phase III Trial in Active Thyroid Eye Disease Transcript

Viridian's REVEAL-1: Clinically Active But Not Market-Dominating, Shares React Badly

Viridian Therapeutics (VRDN) Soars 5.6%: Is Further Upside Left in the Stock?

Viridian Therapeutics Crashes On 'Positive, But Lackluster' Thyroid Eye Disease Results

비리디안 테라퓨틱스, Leerink 컨퍼런스서 시장 확대 모색

Viridian Therapeutics at Leerink Conference: Eyeing Market Expansion